Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 9:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 284 matching trials from the live ClinicalTrials.gov search.
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
0.9% Sodium Chloride, Furosemide 40 mg
Drug
Lead sponsor
Adhish Agarwal
Other
Eligibility
21 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Heart Failure
Interventions
BMS-986435, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
40 Years to 85 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
23
States / cities
Birmingham, Alabama • Lakewood, Colorado • Jacksonville, Florida + 18 more
Recruiting Not applicable Interventional

ELEVATE-HFpEF Clinical Study

NCT06678841
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
Personalized cardiac pacing
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
40 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
26
States / cities
Phoenix, Arizona • Palo Alto, California • San Francisco, California + 22 more
Recruiting No phase listed Observational Accepts healthy volunteers

Exercise Intolerance in Heart Failure

NCT03775577
Conditions
Heart Failure With Normal Ejection Fraction
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction, Diastolic Heart Failure
Interventions
Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, OPTIMIZER™ Smart Mini System
Device
Lead sponsor
Impulse Dynamics
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
105
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 79 more
Conditions
Heart Failure, Preserved Ejection Fraction
Interventions
retrospective observation
Other
Lead sponsor
Ascension Macomb-Oakland Hospital
Other
Eligibility
Not listed
Enrollment
492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Warren, Michigan
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Macitentan, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
24
States / cities
Phoenix, Arizona • Beverly Hills, California • San Diego, California + 20 more
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
multi-domain behavioral, coaching, and exercise protocol
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Congestive Heart Failure, Heart Failure, Left-Sided, Left-Sided Heart Failure
Interventions
Albuterol, Saline placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Recruiting No phase listed Observational

WISE CVD - Continuation (WISE HFpEF)

NCT02582021
Conditions
Microvascular Coronary Dysfunction, Cardiovascular Disease
Interventions
Coronary Angiography, Coronary Reactivity Testing, Cardiac Magnetic Resonance Imaging, Cardiac Magnetic Resonance Angiography, Computed Coronary Tomographic Angiography, Rest-Stress Millar Testing, Aortic vasorelaxation tests
Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Withdrawn Not applicable Interventional Accepts healthy volunteers

Understanding the Mechanisms of Diastolic Dysfunction

NCT03340233
Conditions
Heart Failure With Preserved Ejection Fraction, Healthy
Interventions
MRI (cardiac) off-label use gadolinium contrast (IND exempt), MRI (cardiac)
Diagnostic Test
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Chronic Heart Failure With Preserved Ejection Fraction
Interventions
Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
45 Years and older
Enrollment
789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
29
States / cities
Beverly Hills, California • Carmichael, California • West Hills, California + 26 more
Conditions
Heart Failure, Diastolic
Interventions
Furosemide, Dopamine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Fontan Circulation, Single Ventricle Heart Disease, HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions
Dapagliflozin tablet, Placebo Tablet
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Withdrawn Phase 2 Interventional Accepts healthy volunteers

The Effect of Inflammation in Heart Failure

NCT05330013
Conditions
Myocardial Dysfunction, Heart Failure, Inflammation
Interventions
Dapagliflozin, MRI scan, CMR imaging
Drug · Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 90 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
Dapagliflozin, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 150 Years
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
25
States / cities
Alexander City, Alabama • Fort Payne, Alabama • Beverly Hills, California + 21 more
Conditions
Heart Failure, Congestive Heart Failure
Interventions
Isosorbide Dinitrate, Isosorbide Dinitrate + Hydralazine, Placebo
Drug
Lead sponsor
Corporal Michael J. Crescenz VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Chest Pain, Shortness of Breath
Interventions
Echocardiogram
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Durham, North Carolina
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

The Effect of Adiposity on Muscle and Microvascular Function in HFpEF

NCT06930495
Conditions
Heart Failure With Preserved Ejection Fraction (HFPEF)
Interventions
Weight loss SOC Treatment with second generation anti-diabetic medications
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Terminated Not applicable Interventional Results available

Cardiovascular Improvements With MV ASV Therapy in Heart Failure

NCT01953874
Conditions
Acute Decompensated Heart Failure, Sleep Disordered Breathing
Interventions
MV ASV, Optimized Medical Treatment
Device · Drug
Lead sponsor
ResMed
Industry
Eligibility
21 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
14
States / cities
Huntsville, Alabama • Los Angeles, California • Denver, Colorado + 11 more
Conditions
Heart Failure With Preserved Ejection Fraction, Diastolic Heart Failure
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
21 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Ketone ester, placebo drink
Dietary Supplement
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 85 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
STM01
Drug
Lead sponsor
Secretome Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
2
States / cities
Chicago, Illinois • Dallas, Texas
Conditions
Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases, Cardiovascular Diseases, Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction
Interventions
Pulmonary Artery Denervation (PADN), Sham procedure control
Device
Lead sponsor
Pulnovo Medical, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
12
States / cities
Tucson, Arizona • New Haven, Connecticut • Weston, Florida + 8 more